Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.22+2.52%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Telomir completed the acquisition of TELI Pharmaceuticals in April 2026. The company reported promising preclinical data showing reduced tumor growth in triple-negative breast cancer. Management aims to resolve the delisting notice and enhance strategic partnerships. Revenue is expected around $1.5 million in 2026 despite losses.
Telomir remains loss-making with a mean EPS of -$0.28 expected in 2026. The CFO recently departed, and the company faces regulatory risks from a delisting notice. The acquisition and equity sales may dilute value. Revenue growth and profitability remain uncertain.
The market is selling off the stock amid regulatory and management concerns. There is no clear consensus revenue growth or fair value priced in. Our view is cautious given the loss-making status and uncertain turnaround progress.
Breaks if: Acquisition integration delays or failures reported in 2026
Breaks if: Delisting notice unresolved or escalated beyond 2026
Revenue falls below $1.5 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
TELO represents a speculative growth investment with a focus on clinical development in healthcare. The current thesis state is marked by uncertainty due to recent management changes and ongoing litigation.
The market appears to be pricing in a high level of risk, reflecting TELO's loss-making status and volatile management. There is a significant expectation gap given the recent challenges and the mixed progress on key management priorities.
Fundamentals are likely to remain under pressure due to the company's loss-making status and the high probability of missing earnings expectations. Recent management efforts show mixed results, particularly in advancing clinical trials and integrating acquisitions.
The long-term thesis hinges on the performance of sector bellwethers and their impact on TELO. Additionally, successful execution of clinical trials and resolution of recent litigation will be critical for future performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No new or expanded partnerships by end of 2026
In the next 1 to 3 years, TELO's outlook is clouded by high risk and management volatility. Not investment advice.